For the latest COVID-19 Travel restrictions and recommendations please click here

Science highlighted cancer immunotherapy as the “2013 Breakthrough of the Year”. More to the point, they stated "this year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off - even if the future remains a question mark." Most of the celebration involves the compelling results of targeted agents designed to reactivate the immune system by manipulating the PD-1/PD-L1 and CTLA-4 pathways.

By blocking these recently identified suppressor molecules, these targeted therapies are designed to unleash the immune system either as monotherapies or in combination with traditional cytotoxic chemotherapy. While these investigations have provided a novel direction for enhancing cancer treatment, additional technologies still need to be developed to specifically identify tumor-associated antigens (TAAs) to harness the full power of the immune system. Active specific immunotherapy (ASI) with cancer vaccines has the potential to be that transformative technology by embracing the recently demonstrated genomic heterogeneity of tumor cells which represent the entire antigenic diversity of each patient’s primary tumor.

Fundamental learning objectives: 

• The impact in Antigen discovery for Cancer Vaccines.

• Patient population selection for treatment.

• In vivo and in vitro monitoring of the treatment and clinical endpoints.

• Potential for development of epitope based vaccines for treatment and prevention.

Workshop LEADER


Michael Hanna

Founder & Emeritus, Vaccinogen

Dr. Michael G. Hanna, Jr. received his PhD in experimental pathology and immunology from the University of Tennessee in 1964. He was on staff of the Oak Ridge National Laboratory, biology division from 1964-75. During this period he pioneered the early concepts of tumor immunology. He also served as a consultant with NASA for the lunar receiving laboratory during Apollo 11 and 12, for which his expertise in immunology was used in the testing of the lunar core powder for immunogenic or pathogenic materials. Dr. Hanna served during1975–83 as Director of the National Cancer Institute, Frederick Cancer Research Center (MD, USA). In this position he created a center of research excellence for the NCI and established the Biological Response Modifier Program which led in the development of resources for immunotherapy of cancer.

He was Chief Operating Officer during 1984–94 of Organon Teknika/Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, The Netherlands. He developed and obtained approvals for TICE BCG for the treatment of carcinoma in situ (CIS) bladder cancer, which remains the standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. Subsequently, Dr. Hanna founded PerImmune Inc., for which he served as President and Chief Executive Officer before it merged with Intracel Corp. in1998. He continued to work for Intracel Resources as Chief Scientific Officer and Chairman.


Vaccinogen, Inc. is a cancer vaccine company that is clinically testing its OncoVAX® treatment which is designed to prevent the recurrence of colon cancer and potentially other solid tumors. It is a patented process that circumvents the extreme diversity of tumor cells by leveraging a patient’s own live tumor cells to launch a broad immune response against colon cancer. The Company believes that OncoVAX, at an optimum dose and regimen, is the first colon cancer vaccine to demonstrate effectiveness in both preventing cancer recurrence after surgical resection of the primary tumor and addressing the diversity of cancer cells. OncoVAX has completed five clinical studies, including a Phase III trial with the optimum dose and regimen. The Company expects to begin a pivotal Phase IIIb trial under an FDA Special Protocol Assessment (SPA) classification in the second quarter of 2015. The Company’s shares trade on the OTC.QB under the symbol “VGEN”. More information is available at www.vaccinogeninc.com.

Workshop programme

13:30 Registration and Coffee

Michael Hanna

Michael Hanna, Founder & Emeritus, Vaccinogen
View Bio

14:00 The impact in Antigen discovery for Cancer Vaccines

Michael Hanna

Michael Hanna, Founder & Emeritus, Vaccinogen
View Bio

15:00 Afternoon Tea

15:30 Patient population selection for treatment.

Michael Hanna

Michael Hanna, Founder & Emeritus, Vaccinogen
View Bio

16:30 Potential for development of epitope based vaccines for treatment and prevention.

Michael Hanna

Michael Hanna, Founder & Emeritus, Vaccinogen
View Bio

17:00 Chairman’s Closing Remarks and Close of Day One

Michael Hanna

Michael Hanna, Founder & Emeritus, Vaccinogen
View Bio


Marriott Hotel Regents Park

128 King Henry’s Road
London NW3 3ST
United Kingdom

Marriott Hotel Regents Park

This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.



speaker image






CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title


Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event


Sign up
Forgotten Password?


UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71

Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out